Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 3, 2002, Pages 145-154

  Andersson, Borje S ^a   Kashyap, Ashwin ^a   Gian, Victor ^a   Wingard, John R ^a   Fernandez, Hugo ^a   Cagnoni, Pablo J ^a   Jones, Roy B ^a   Tarantolo, Stefano ^a   Hu, Wendy W ^a   Blume, Karl G ^a   Forman, Stephen J ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Busulfan; Cyclophosphamide; Intravenous busulfan

Indexed keywords

ANTIEMETIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MESNA; METHOTREXATE; MOLECULAR MARKER; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIVER TOXICITY; LIVING DONOR; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; SIBLING; VEIN OCCLUSION; ALLOTRANSPLANTATION; BLOOD DISEASE; GRAFT SURVIVAL; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MORTALITY; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036205591     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm11939604     Document Type: Article

References (51)

1. Overview of stem cell transplantation
2. Growth in children following irradiation for bone marrow transplantation
3. Bone marrow transplantation for pediatric leukemia
4. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood
5. Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood
6. Malignant neoplasms following bone marrow transplantation
7. Toxicities of total-body irradiation for pediatric bone marrow transplantation
8. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients
9. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood
10. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers
11. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia
12. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide
13. Preliminary results of highdose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue
14. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
15. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen: Low incidence of failed engraftment and severe acute GVHD
16. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
17. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
18. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease
19. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
20. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
21. Pharmacokinetic and metabolic studies of high-dose busulphan in adults
22. Association of busulfan area under the curve with veno-occlusive disease following BMT
23. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis
24. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors
25. Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study
26. Busulfan bioavailability
27. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
28. Individualizing highdose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
29. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: Rationale and pitfalls
30. Busulfan
31. Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted?
32. Formulation and stability of busulfan for intravenous administration in highdose chemotherapy
33. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy; a phase I study
34. Nonparametric estimation from incomplete observations
35. Veno-occlusive disease of the liver following bone marrow transplantation
36. Gas chromotographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard
37. Noncompartmental analysis based on statistical moment theory
38. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation
39. Survival and toxicity update following tandem cycle high-dose melphalan (Mel) and busulfan cyclophosphamide (BuCy) with autologous peripheral blood progenitor cell rescue (PBPC) in multiple myeloma (MM): Lack of the incidence of hepatic veno-occlusive disease (VOD) and busulfan pharmacokinetics
40. Allogeneic blood stem cell transplantation in advanced hematologic cancers
41. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma
42. Intravenous (IV) vs oral busulfan (BU) as part of a BU/CY (Cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): Decreased incidence of hepatic veno-occlusive disease (VOD)
43. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan (BU) containing preparative regimen for hematopoietic stem cell transplantation (HSCT)
44. Intravenous busulfan (Busulfex)/cytoxan (cy) preparative regimen for allogeneic (allo) and autologous (auto) haematopoietic stem cell transplantation (BMT) is well tolerated by patients over 50 years of age
45. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
46. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders
47. Pharmacokinetic based individualized IV busulfan therapy in marrow transplant preparative regimens